摘要
目的探讨血清生存素(survivin)测定在乳腺癌诊断中的临床意义。方法采用酶联免疫吸附试验(ELISA)定量检测健康对照组(22例健康体检者)、乳腺癌患者无转移组(24例)和乳腺癌患者有远处转移组(32例)血清survivin蛋白的表达水平。结果健康对照组血清survivin表达水平为0.31±0.06 ng/ml;无转移的乳腺癌患者sur-vivin表达水平为0.49±0.05 ng/ml;有转移的乳腺癌患者survivin表达水平为1.02±0.18 ng/ml。统计软件分析显示与健康对照组相比,survivin在乳腺癌患者(包括无转移组和转移组)的表达升高(P<0.01);而乳腺癌转移组中survivin的表达明显高于无转移组(P<0.01)。结论血清survivin的蛋白质表达的定量检测可作为乳腺癌发生和转移的预警指标之一。
Objective To observe the clinical significance of serum survivin determination in diagnosis of breast cancer. Methods The quantitative protein level of serum survivin was measured by enzyme - linked immunosorbentassay (ELISA) in control group (22 cases of healthy person) ,non -metastatic breast cancer group (24 cases) and metastatic breast cancer group (32 cases). Results The protein expression level of survivin in control group is 0.31 ± 0.06 ng/ml; The protein expression level of survivin in non - metastatic breast cancer group is 0.49 ± 0.05 ng/ ml; The protein expression level of survivin in metastatic breast cancer group is 1.02 ±0.18 ng/ml. When comparing with the control group,the expression of survivin increased both in non -metastatic and metastatic breast cancer groups ( P 〈 0.01 ) analyzed by stabistics software;There are significant differences of survivin expression in non - metastatic and metastatic breast cancer groups ( P 〈 0.01 ). Conclusion The quantitative detection of serum survivin can be a precaution index of the breast cancer genesis and metaptosis.
出处
《临床和实验医学杂志》
2012年第11期823-824,共2页
Journal of Clinical and Experimental Medicine
基金
四川省卫生厅科研项目(编号:100162)